BioOva Oocyte Extract Disease treatment products have been tested in the Human & Animal models listed below and has been administered by several methods including subcutaneously, intraperitoneally, intratumorally, and topically. These studies have served to highlight broad potential across a range of tissues and administration methods, as well as to validate the universal nature of its tissue remodeling concept.
Key Human Treatment Results with Bioova Oocyte Extract:
Other ares of use for BioOva Oocyte extract:
Traumatic Brain Injury (TBI) – BioOva demonstrated improvement in gross anatomical changes, reductions in B-amyloid protein expression, and improvements in hippocampus impaired spatial learning and memory.
Melanoma – BioOva demonstrated shrinkage of tumor size, prevention of new tumor formation, and reduction in tumor invasiveness biomarkers
Skin Wrinkling – BioOva demonstrated enhanced reversal of skin wrinkling
Hair Loss (Alopecia) – BioOva demonstrated re-growth of hair
Gerontological (Aging) – conducted chronic administration in both mice and fruit flies (Drosophila melanogaster) – Experimental mice lived 1.7 times longer than animals in control group and experimental Drosophila melanogaster flies lived 2.2 times longer than control group.
The longest administration of BQ-A in a disease model has been 45 days. The longest administration in a healthy animal has been for over one year. While not a formal safety study, from an observational perspective no growths, abscesses, infections, immune reactions, or behavioral changes have been seen in these animals, highlighting an intriguing and promising safety profile.